U.S. Virgin Islands:
18-8 Estate Smith Bay
Top Floor
St. Thomas, USVI 00802
Tel: 340-779-6908
Fax: 340-714-5192
Mailing Address:
6501 Redhook Plaza, Suite 201
St. Thomas, USVI 00802
New York :
663 Fifth Avenue
New York, New York 10022
Tel: 212-616-4061
News
01/10/11
Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Opthamology
[PDF]
12/15/10
Celtic Therapeutics and Bellus Health Initiate Confirmatory Phase III Clinical Study for Kiacta™, a Drugs Candidate for the Treatment of AA Amyloidosis
[PDF]
10/26/10
Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
[PDF]
09/15/10
Spirogen and Celtic Therapeutics Commence a Phase II Clinical Trial of SG2000 in Ovarian Cancer
[PDF]
04/29/10
Bellus Health and Celtic Therapeutics Enter Agreement for Bellus’ Drug Candidate Kiacta™
[PDF]
01/19/10
CT Leads Series B Investment in Kolltan Pharmaceuticals
[PDF]
10/27/09
PPD to Invest in Celtic Therapeutics
[PDF]
10/08/09
Celtic Therapeutics to invest up to $15m in the development
of Spirogen’s cancer drug SG2000
[PDF]
12/19/08
Celtic Therapeutics Announces First Closing and Two Senior Appointments
[PDF]
12/18/07
Ex-Pfizer Research Chief Resumes Hunt For Drugs
Wall Street Journal Online
12/18/07
Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner
[PDF]
© 2007 Celtic Therapeutics
>
Websites for Professional Services